藥品參考
Pralsetinib
Pralsetinib is a medicine in the class oncology. It is used for non-small cell lung cancer.
- 藥物類別: Oncology
- 用途: non-small cell lung cancer
最後更新 來源: US FDA label
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
重點資訊
- 藥物類別
- Oncology
- 常見劑型
- 膠囊
- 常見規格
- 100 mg
- 已知交互作用
- 16 (嚴重: 15 · 中度: 1)
- 商品名
- 1
- 國家與市場
- 1
用途
作用方式
Kinase inhibitor of wild-type RET and oncogenic RET fusions and mutations (IC50s less than 0.5 nM); inhibits downstream signaling that drives uncontrolled cell proliferation.
成人常用劑量（仿單摘要）
RET fusion-positive NSCLC or thyroid cancer: 400 mg orally once daily on an empty stomach (no food for at least 2 hours before and at least 1 hour after); continue until disease progression or unacceptable toxicity
懷孕與哺乳
- 懷孕
- Unsafe Can cause fetal harm: in rats it caused malformations and embryo death below human exposure; no human data. Avoid in pregnancy; check pregnancy status. Women: non-hormonal contraception during treatment and for 2 weeks after (it may make hormonal methods fail); men: 1 week.
- 哺乳
- Unsafe No data on passage into milk; it is 97% protein bound, but its 22-hour half-life may allow build-up in the infant (LactMed). Do not breastfeed during treatment and for 1 week after the last dose.
已通報的副作用
- Musculoskeletal pain
- Constipation
- Hypertension
- Diarrhea
- Fatigue
- Edema
黑框警語
- May increase the risk of serious bacterial, fungal, viral and opportunistic infections, which can lead to hospitalization or death. Withhold, reduce the dose or permanently discontinue based on severity.
哪些人需要特別留意
- Serious infections, including opportunistic and fatal infections: monitor for signs and symptoms and treat appropriately.
- Interstitial lung disease/pneumonitis can be severe, life-threatening or fatal; withhold and investigate for acute or worsening respiratory symptoms.
- Hypertension: do not initiate in uncontrolled hypertension; monitor BP after 1 week and at least monthly thereafter.
請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏，以及您正在使用的所有其他藥物或保健品。
重要交互作用 (16)
- Amobarbital + Pralsetinib Major
- Apalutamide + Pralsetinib Major
- Carbamazepine + Pralsetinib Major
- Chloramphenicol + Pralsetinib Major
- Clarithromycin + Pralsetinib Major
- Efavirenz + Pralsetinib Major
- Enzalutamide + Pralsetinib Major
- Itraconazole + Pralsetinib Major
- Ketoconazole + Pralsetinib Major
- Lorlatinib + Pralsetinib Major
Pro+ 會員專屬
解鎖完整頁面
建立帳號並開始 Pro+ 試用，即可開啟 Pralsetinib 的完整藥品專論：劑量、懷孕與哺乳、副作用、警示及所有交互作用。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
在網頁版免費試用 Pro+ 14 天，無需信用卡。
同類別的其他藥品
常見問題
What is Pralsetinib used for?
Pralsetinib is a medicine in the class oncology. It is used for Non-small cell lung cancer, Thyroid cancer.
What side effects have been reported with Pralsetinib?
Musculoskeletal pain, Constipation, Hypertension, Diarrhea, Fatigue, Edema. Serious warning: May increase the risk of serious bacterial, fungal, viral and opportunistic infections, which can lead to hospitalization or death.
Can Pralsetinib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: in rats it caused malformations and embryo death below human exposure; no human data. Avoid in pregnancy; check pregnancy status. Women: non-hormonal contraception during treatment and for 2 weeks after (it may make hormonal methods fail); men: 1 week. Breastfeeding: Unsafe. No data on passage into milk; it is 97% protein bound, but its 22-hour half-life may allow build-up in the infant (LactMed). Do not breastfeed during treatment and for 1 week after the last dose.
What does Pralsetinib interact with?
MediHelp lists 16 known interactions for Pralsetinib. Major: 15 · Moderate: 1. The most serious include Amobarbital, Apalutamide, Carbamazepine.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
